Nirsevimab
Based on 2 publication(s) in Google Scholar
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.
For research use only. We do not sell to patients.
- Purity: 98.63%
- CAS No.: 1989556-22-0
- Molecular Weight:146.31 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nirsevimab
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
Human IgG1 kappa
Human
RSV-F
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:3-week-old female BALB/c mice[2].
-
Dosage:10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg
-
Administration:Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure
-
Result:Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
A0A0X8XRK2
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Nirsevimab. The EC50 for this effect is 44 ng/mL.
Chemical Information
-
CAS No. 1989556-22-0
-
Appearance Liquid
-
Molecular Weight 146.31 kDa
-
Color Colorless to light yellow
-
SMILES
[Nirsevimab]
-
Synonyms
MEDI8897
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Med Virol
Development of a HEp2-CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation. [Abstract]2025 Sep;97(9):e70601. PMID: 40947663 -
Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.
All MARMs could be rescued by at least one other mAb. Three RSM01 MARMs (RSM-1 to RSM-3) could still be neutralised by nirsevimab and clesrovimab.
Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.
RSV-B isolates displayed 17 highly variable positions, two of which are located in overlapping RSM01/nirsevimab binding sites.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. [Content Brief]
[2]. Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nirsevimab Related Classifications
HY-P99756 Related Classifications
Powered by Bioz